Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time — they are meant to enhance the immune system’s destruction of tumor cells. While new T cell-based immunotherapies, or “T-cell redirection” therapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have revolutionized cancer treatment, doctors still need to determine what second-line treatments (also known as salvage therapy) are effective after a patient relapses. In the August 26 online edition of Blood Advances, Mount Sinai researchers report that sequential use of different T-cell redirection therapies in these multiple myeloma patients is possible and could lead to good patient outcomes and survival. In a retrospective analysis, researchers identified 58 multiple myeloma patients who participated in a bispecific antibody clinical trial at Mount Sinai and underwent salvage therapy due to relapse. Patients were followed for an average of 30.5 months after the end of the trial and underwent an average of two salvage therapies over that period.